Oisín Biotechnologies Publishes Preclinical Data on Muscle Gene Therapy in Cell

Oisín Biotechnologies, a private biotech firm focused on combating age-related diseases, announced the publication of preclinical data from its follistatin (FST) gene therapy program aimed at reducing muscle loss. The research, titled “Safe and Effective Delivery of DNA and RNA…

Read MoreOisín Biotechnologies Publishes Preclinical Data on Muscle Gene Therapy in Cell

JuneBrain Wins MDIC Award; Chooses Compliance Group for Siemens Polarion Implementation

JuneBrain is thrilled to announce that it has received a $300,000 grant from the Medical Device Innovation Consortium’s Advanced Manufacturing Clearing House program. The funding will support the modernization of JuneBrain’s quality management system in collaboration with Compliance Group (CG)…

Read MoreJuneBrain Wins MDIC Award; Chooses Compliance Group for Siemens Polarion Implementation

Novel TROP2 Biomarker Predicts Outcomes for Datopotamab Deruxtecan in NSCLC: TROPION-Lung01 Phase III

An exploratory analysis of the TROPION-Lung01 Phase III trial found that the TROP2 biomarker, assessed via AstraZeneca’s computational pathology platform, Quantitative Continuous Scoring (QCS), effectively predicted clinical outcomes in patients with advanced or metastatic non-small cell lung cancer (NSCLC) treated…

Read MoreNovel TROP2 Biomarker Predicts Outcomes for Datopotamab Deruxtecan in NSCLC: TROPION-Lung01 Phase III

Phase 3 CAMZYOS® (mavacamten) Study Confirms Efficacy and Safety for Obstructive Hypertrophic Cardiomyopathy

Bristol Myers Squibb (NYSE: BMY) has announced new long-term follow-up data from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension (LTE) study. This data evaluates the efficacy and safety of CAMZYOS® (mavacamten) in adults with New York Heart Association (NYHA) class…

Read MorePhase 3 CAMZYOS® (mavacamten) Study Confirms Efficacy and Safety for Obstructive Hypertrophic Cardiomyopathy

Sensorion to Lead Hearing Loss Symposium at World Congress of Audiology 2024 in Paris

Sensorion (FR0012596468 – ALSEN), a leading clinical-stage biotechnology company focused on innovative therapies for hearing loss, has announced its participation in the 36th World Congress of Audiology (WCA) in Paris from September 19-22, 2024. The company will host a symposium…

Read MoreSensorion to Lead Hearing Loss Symposium at World Congress of Audiology 2024 in Paris

EDX Medical Partners with Caris Life Sciences for Molecular Profiling Distribution in UK and Nordic Countries

EDX Medical Group plc, a company focused on innovative digital diagnostics for personalized treatment in cancer, heart disease, and infectious diseases, has signed a distribution agreement with Caris Life Sciences®. Caris, a U.S.-based leader in next-generation AI TechBio and precision…

Read MoreEDX Medical Partners with Caris Life Sciences for Molecular Profiling Distribution in UK and Nordic Countries